Synthesis and transport of creatine in the CNS: Importance for cerebral functions

Journal of Neurochemistry

Volumn 115, Issue 2, 2010, Pages 297-313

  Béard, Elidie ^a   Braissant, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Brain; Creatine; Creatine deficiency; Guanidinoacetate; Mitochondria; Neuroprotection

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID TRANSPORTER; AMMONIA; AMYLOID BETA PROTEIN; CREATINE KINASE; CREATINE PHOSPHATE; CREATININE; CREATININE TRANSPORTER; GLYCINE AMIDINOTRANSFERASE; GUANIDINOACETATE METHYLTRANSFERASE; HUNTINGTIN; NEUROTRANSMITTER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; AMINO ACID TRANSPORT; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN ISCHEMIA; CREATININE TRANSPORTER DEFICIENCY; DIET SUPPLEMENTATION; GLYCINE AMIDINOTRANSFERASE DEFICIENCY; GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY; HUMAN; HUNTINGTON CHOREA; HYPERAMMONEMIA; INBORN ERROR OF METABOLISM; MEMBRANE PERMEABILITY; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETINA GYRATE ATROPHY; REVIEW; STROKE;

AMIDINOTRANSFERASES; ANIMALS; CENTRAL NERVOUS SYSTEM; CEREBRAL CORTEX; CREATINE; GUANIDINOACETATE N-METHYLTRANSFERASE; HUMANS; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; PROTEIN TRANSPORT;

EID: 78651274358     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06935.x     Document Type: Review

References (189)

1. Acosta M. L., Kalloniatis M. and Christie D. L. (2005) Creatine transporter localization in developing and adult retina: Importance of creatine to retinal function. Am. J. Physiol. Cell Physiol. 289, C1015-C1023.
2. Adhihetty P. J. and Beal M. F. (2008) Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular. Med. 10, 275-290.
3. Aksenov M., Aksenova M., Butterfield D. A. and Markesbery W. R. (2000) Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74, 2520-2527.
4. Alfieri R. R., Bonelli M. A., Cavazzoni A. et al. (2006) Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. J. Physiol. 576, 391-401.
5. Almeida L. S., Rosenberg E. H., Verhoeven N. M., Jakobs C. and Salomons G. S. (2006a) Are cerebral creatine deficiency syndromes on the radar screen? Fut. Neurol. 1, 637-649.
6. Almeida L. S., Salomons G. S., Hogenboom F., Jakobs C. and Schoffelmeer A. N. (2006b) Exocytotic release of creatine in rat brain. Synapse 60, 118-123.
7. Andreassen O. A., Dedeoglu A., Ferrante R. J. et al. (2001) Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8, 479-491.
8. Andres R. H., Ducray A. D., Schlattner U., Wallimann T. and Widmer H. R. (2008) Functions and effects of creatine in the central nervous system. Brain Res. Bull. 76, 329-343.
9. Arias A., Corbella M., Fons C. et al. (2007) Creatine transporter deficiency: Prevalence among patients with mental retardation and pitfalls in metabolite screening. Clin. Biochem. 40, 1328-1331.
10. Balestrino M., Rebaudo R. and Lunardi G. (1999) Exogenous creatine delays anoxic depolarization and protects from hypoxic damage: Dose-effect relationship. Brain Res. 816, 124-130.
11. Balestrino M., Lensman M., Parodi M., Perasso L., Rebaudo R., Melani R., Polenov S. and Cupello A. (2002) Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage. Amino Acids 23, 221-229.
12. Battini R., Leuzzi V., Carducci C., Tosetti M., Bianchi M. C., Item C. B., Stöckler-Ipsiroglu S. and Cioni G. (2002) Creatine depletion in a new case with AGAT deficiency: Clinical and genetic study in a large pedigree. Mol. Genet. Metab. 77, 326-331.
13. Battini R., Alessandri M. G., Leuzzi V., Moro F., Tosetti M., Bianchi M. C. and Cioni G. (2006) Arginine: Glycine amidinotransferase (AGAT) deficiency in a newborn: Early treatment can prevent phenotypic expression of the disease. J. Pediatr. 148, 828-830.
14. Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357-366.
15. Beal M. F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23, 298-304.
16. Beal M. F. (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N Y Acad. Sci. 991, 120-131.
17. Beal M. F. and Ferrante R. J. (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5, 373-384.
18. Beal M. F. and Martin J. B. (1998) Major complications of cirrhosis, in Harrison's Principles of Internal Medicine (Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B., Kasper D. L., Hauser S. L. and Longo D. L., eds), pp. 2451-2457. McGraw-Hill, New-York.
19. Bélanger M., Asashima T., Ohtsuki S., Yamaguchi H., Ito S. and Terasaki T. (2007) Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochem. Int. 50, 95-101.
20. Bender A., Auer D. P., Merl T. et al. (2005) Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol. 252, 36-41.
21. Bender A., Koch W., Elstner M. et al. (2006) Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology 67, 1262-1264.
22. Bernardi P., Colonna R., Costantini P. et al. (1998) The mitochondrial permeability transition. Biofactors 8, 273-281.
23. Bindoff L. A., Birch-Machin M., Cartlidge N. E., Parker W. D. and Turnbull D. M. (1989) Mitochondrial function in Parkinson's disease. Lancet 2, 49.
24. Bizzi A., Bugiani M., Salomons G. S., Hunneman D. H., Moroni I., Estienne M., Danesi U., Jakobs C. and Uziel G. (2002) X-linked creatine deficiency syndrome: A novel mutation in creatine transporter gene SLC6A8. Ann. Neurol. 52, 227-231.
25. Borthwick G. M., Johnson M. A., Ince P. G., Shaw P. J. and Turnbull D. M. (1999) Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death. Ann. Neurol. 46, 787-790.
26. Bothwell J. H., Rae C., Dixon R. M., Styles P. and Bhakoo K. K. (2001) Hypo-osmotic swelling-activated release of organic osmolytes in brain slices: Implications for brain oedema in vivo. J. Neurochem. 77, 1632-1640.
27. Bouras C., Hof P. R., Giannakopoulos P., Michel J. P. and Morrison J. H. (1994) Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: A quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb. Cortex 4, 138-150.
28. Braissant O. (2010a) Current concepts in the pathogenesis of urea cycle disorders. Mol. Gen. Metab. 100, S3-S12.
29. Braissant O. (2010b) Ammonia toxicity to the brain: Effects on creatine metabolism and transport and protective roles of creatine. Mol. Gen. Metab. 100, S53-S58.
30. Braissant O. and Henry H. (2008) AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: A review. J. Inherit. Metab. Dis. 31, 230-239.
31. Braissant O., Henry H., Loup M., Eilers B. and Bachmann C. (2001) Endogenous synthesis and transport of creatine in the rat brain: An in situ hybridization study. Mol. Brain Res. 86, 193-201.
32. Braissant O., Henry H., Villard A. M. et al. (2002) Ammonium-induced impairment of axonal growth is prevented through glial creatine. J. Neurosci. 22, 9810-9820.
33. Braissant O., Henry H., Villard A. M., Speer O., Wallimann T. and Bachmann C. (2005) Creatine synthesis and transport during rat embryogenesis: Spatiotemporal expression of AGAT, GAMT and CT1. BMC Dev. Biol. 5, 9.
34. Braissant O., Bachmann C. and Henry H. (2007) Expression and function of AGAT, GAMT and CT1 in the mammalian brain. Subcell. Biochem. 46, 67-81.
35. Braissant O., Cagnon L., Monnet-Tschudi F., Speer O., Wallimann T., Honegger P. and Henry H. (2008) Ammonium alters creatine transport and synthesis in a 3D culture of developing brain cells, resulting in secondary cerebral creatine deficiency. Eur. J. Neurosci. 27, 1673-1685.
36. Braissant O., Béard E., Torrent C. and Henry H. (2010) Dissociation of AGAT, GAMT and SLC6A8 in CNS: Relevance to creatine deficiency syndromes. Neurobiol. Dis. 37, 423-433.
37. Brewer G. J. and Wallimann T. W. (2000) Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J. Neurochem. 74, 1968-1978.
38. Brosnan J. T. and Brosnan M. E. (2007) Creatine: Endogenous metabolite, dietary, and therapeutic supplement. Annu. Rev. Nutr. 27, 241-261.
39. Brosnan J. T., Wijekoon E. P., Warford-Woolgar L., Trottier N. L., Brosnan M. E., Brunton J. A. and Bertolo R. F. (2009) Creatine synthesis is a major metabolic process in neonatal piglets and has important implications for amino acid metabolism and methyl balance. J. Nutr. 139, 1292-1297.
40. Brouillet E. and Beal M. F. (1993) NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport 4, 387-390.
41. Bürklen T. S., Schlattner U., Homayouni R., Gough K., Rak M., Szeghalmi A. and Wallimann T. (2006) The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits. J. Biomed. Biotechnol. 2006, 35936.
42. Cagnon L. and Braissant O. (2007) Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res. Rev. 56, 183-197.
43. Cagnon L. and Braissant O. (2008) Role of caspases, calpain and cdk5 in ammonia-induced cell death in developing brain cells. Neurobiol. Dis. 32, 281-292.
44. Cagnon L. and Braissant O. (2009) CNTF protects oligodendrocytes from ammonia toxicity: Intracellular signaling pathways involved. Neurobiol. Dis. 33, 133-142.
45. Carlson M. and Van Pilsum J. F. (1973) S-adenosylmethionine: Guanidinoacetate N-methyltransferase activities in livers from rats with hormonal deficiencies or excesses. Proc. Soc. Exp. Biol. Med. 143, 1256-1259.
46. Casey A. and Greenhaff P. L. (2000) Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am. J. Clin. Nutr. 72, 607S-617S.
47. Cecil K. M., Salomons G. S., Ball W. S., Wong B., Chuck G., Verhoeven N. M., Jakobs C. and de Grauw T. J. (2001) Irreversible brain creatine deficiency with elevated serum and urine creatine: A creatine transporter defect? Ann. Neurol. 49, 401-404.
48. Chaturvedi R. K. and Beal M. F. (2008) Mitochondrial approaches for neuroprotection. Ann. N Y Acad. Sci. 1147, 395-412.
49. Chen N. H., Reith M. E. and Quick M. W. (2004) Synaptic uptake and beyond: The sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. 447, 519-531.
50. Chilosi A., Leuzzi V., Battini R. et al. (2008) Treatment with L-Arginine improves neuropsychological disorders in a child with creatine transporter defect. Neurocase 14, 151-161.
51. Choi C. G. and Yoo H. W. (2001) Localized proton MR spectroscopy in infants with urea cycle defect. AJNR Am. J. Neuroradiol. 22, 834-837.
52. Clark A. J., Rosenberg E. H., Almeida L. S., Wood T. C., Jakobs C., Stevenson R. E., Schwartz C. E. and Salomons G. S. (2006) Xlinked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. Hum. Genet. 119, 604-610.
53. Cupello A., Balestrino M., Gatta E., Pellistri F., Siano S. and Robello M. (2008) Activation of cerebellar granule cells GABA(A) receptors by guanidinoacetate. Neuroscience 152, 65-69.
54. Dai W., Vinnakota S., Qian X., Kunze D. L. and Sarkar H. K. (1999) Molecular characterization of the human CRT-1 creatine transporter expressed in Xenopus oocytes. Arch. Biochem. Biophys. 361, 75-84.
55. Daly M. M. (1985) Guanidinoacetate methyltransferase activity in tissues and cultured cells. Arch. Biochem. Biophys. 236, 576-584.
56. 2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J. Neurochem. 96, 1349-1361.
57. Davis B. M., Miller R. K., Brent R. L. and Koszalka T. R. (1978) Materno-fetal transport of creatine in the rat. Biol. Neonate 33, 43-54.
58. De Deyn P. P., Marescau B. and Macdonald R. L. (1991) Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture. Epilepsy Res. 8, 134-141.
59. Dedeoglu A., Kubilus J. K., Yang L., Ferrante K. L., Hersch S. M., Beal M. F. and Ferrante R. J. (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85, 1359-1367.
60. Di Lisa F. and Bernardi P. (2005) Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition. Cardiovasc. Res. 66, 222-232.
61. Dickmeis T., Rastegar S., Aanstad P., Clark M., Fischer N., Plessy C., Rosa F., Korzh V. and Strahle U. (2001) Expression of brain subtype creatine kinase in the zebrafish embryo. Mech. Dev. 109, 409-412.
62. Dirnagl U., Iadecola C. and Moskowitz M. A. (1999) Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. 22, 391-397.
63. Donnan G. A., Fisher M., Macleod M. and Davis S. M. (2008) Stroke. Lancet 371, 1612-1623.
64. Dringen R., Verleysdonk S., Hamprecht B., Willker W., Leibfritz D. and Brand A. (1998) Metabolism of glycine in primary astroglial cells: Synthesis of creatine, serine, and glutathione. J. Neurochem. 70, 835-840.
65. Ellington W. R. (2001) Evolution and physiological roles of phosphagen systems. Annu. Rev. Physiol. 63, 289-325.
66. Engelhardt B. (2003) Development of the blood-brain barrier. Cell Tissue Res. 314, 119-129.
67. Ensenauer R., Thiel T., Schwab K. O., Tacke U., Stöckler-Ipsiroglu S., Schulze A., Hennig J. and Lehnert W. (2004) Guanidinoacetate methyltransferase deficiency: Differences of creatine uptake in human brain and muscle. Mol. Gen. Metab. 82, 208-213.
68. Ferrante R. J., Andreassen O. A., Jenkins B. G., Dedeoglu A., Kuemmerle S., Kubilus J. K., Kaddurah-Daouk R., Hersch S. M. and Beal M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397.
69. Fons C., Sempere A., Arias A. et al. (2008) Arginine supplementation in four patients with X-linked creatine transporter defect. J. Inherit. Metab. Dis. 31, 724-728.
70. Fons C., Arias A., Sempere A. et al. (2010) Response to creatine analogs in fibroblasts and patients with creatine transporter deficiency. Mol. Genet. Metab. 99, 296-299.
71. Galbraith R. A., Furukawa M. and Li M. (2006) Possible role of creatine concentrations in the brain in regulating appetite and weight. Brain Res. 1101, 85-91.
72. Gauthier L. R., Charrin B. C., Borrell-Pages M. et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138.
73. Gideon P., Henriksen O., Sperling B., Christiansen P., Olsen T. S., Jorgensen H. S. and Arlien-Soborg P. (1992) Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke 23, 1566-1572.
74. De Grauw T. J., Salomons G. S., Cecil K. M., Chuck G., Newmeyer A., Schapiro M. B. and Jakobs C. (2002) Congenital creatine transporter deficiency. Neuropediatrics 33, 232-238.
75. Green D. R. and Reed J. C. (1998) Mitochondria and apoptosis. Science 281, 1309-1312.
76. Groeneveld G. J., de Leeuw van Weenen J., van Muiswinkel F. L., Veldman H., Veldink J. H., Wokke J. H., Bar P. R. and van den Berg L. H. (2003) Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 352, 175-178.
77. Gropman A. L. and Batshaw M. L. (2004) Cognitive outcome in urea cycle disorders. Mol. Genet. Metab. 81, S58-S62.
78. Gualano B., Artioli G. G., Poortmans J. R. and Lancha A. H. (2010) Exploring the therapeutic role of creatine supplementation. Amino Acids 38, 31-44.
79. (+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. J. Biol. Chem. 268, 8418-8421.
80. Guthmiller P., Van Pilsum J. F., Boen J. R. and McGuire D. M. (1994) Cloning and sequencing of rat kidney L-arginine: Glycine amidinotransferase. Studies on the mechanism of regulation by growth hormone and creatine. J. Biol. Chem. 269, 17556-17560.
81. Happe H. K. and Murrin L. C. (1995) In situ hybridization analysis of CHOT1, a creatine transporter, in the rat central nervous system. J. Comp. Neurol. 351, 94-103.
82. Hemmer W. and Wallimann T. (1993) Functional aspects of creatine kinase in brain. Dev. Neurosci. 15, 249-260. (Pubitemid 24258157)
83. Hemmer W., Zanolla E., Furter-Graves E. M., Eppenberger H. M. and Wallimann T. (1994) Creatine kinase isoenzymes in chicken cerebellum: Specific localization of brain-type creatine kinase in Bergmann glial cells and muscle-type creatine kinase in Purkinje neurons. Eur. J. Neurosci. 6, 538-549.
84. Hersch S. M., Gevorkian S., Marder K. et al. (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66, 250-252.
85. Hervias I., Beal M. F. and Manfredi G. (2006) Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve 33, 598-608.
86. Ireland Z., Russell A. P., Wallimann T., Walker D. W. and Snow R. (2009) Developmental changes in the expression of creatine synthesizing enzymes and creatine transporter in a precocial rodent, the spiny mouse. BMC Dev. Biol. 9, 39.
87. Item C. B., Stöckler-Ipsiroglu S., Stromberger C., Mühl A., Alessandri M. G., Bianchi M. C., Tosetti M., Fornai F. and Cioni G. (2001) Arginine: Glycine amidinotransferase deficiency: The third inborn error of creatine metabolism in humans. Am. J. Hum. Genet. 69, 1127-1133.
88. Jost C. R., Van der Zee C. E., In't Zandt H. J. A., Oerlemans F., Verheij M., Streijger F., Fransen J., Heerschap A., Cools A. R. and Wieringa B. (2002) Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility. Eur. J. Neurosci. 15, 1692-1706.
89. Klein A. M. and Ferrante R. J. (2007) The neuroprotective role of creatine. Subcell. Biochem. 46, 205-243.
90. Klivenyi P., Ferrante R. J., Matthews R. T. et al. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347-350.
91. Kong J. and Xu Z. (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18, 3241-3250.
92. Kreis R., Hofmann L., Kuhlmann B., Boesch C., Bossi E. and Hüppi P. S. (2002) Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy. Magn. Reson. Med. 48, 949-958.
93. Lee H., Ogawa H., Fujioka M. and Gerton G. L. (1994) Guanidinoacetate methyltransferase in the mouse: Extensive expression in Sertoli cells of testis and in microvilli of caput epididymis. Biol. Reprod. 50, 152-162.
94. Lee H., Kim J. H., Chae Y. J., Ogawa H., Lee M. H. and Gerton G. L. (1998) Creatine synthesis and transport systems in the male rat reproductive tract. Biol. Reprod. 58, 1437-1444.
95. Lei H., Berthet C., Hirt L. and Gruetter R. (2009) Evolution of the neurochemical profile after transient focal cerebral ischemia in the mouse brain. J. Cereb. Blood Flow Metab. 29, 811-819.
96. Lensman M., Korzhevskii D. E., Mourovets V. O. et al. (2006) Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat. Brain Res. 1114, 187-194.
97. Leonard J. V. and Morris A. A. (2002) Urea cycle disorders. Semin. Neonatol. 7, 27-35.
98. Li X., Bürklen T., Yuan X., Schlattner U., Desiderio D. M.,Wallimann T. And Homayouni R. (2006) Stabilization of ubiquitous mitochondrial creatine kinase preprotein by APP family proteins. Mol. Cell. Neurosci. 31, 263-272.
99. Lin M. T. and Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795.
100. Lion-François L., Cheillan D., Pitelet G. et al. (2006) High frequency of creatine deficiency syndromes in patients with unexplained mental retardation. Neurology 67, 1713-1714.
101. Lipton P. and Whittingham T. S. (1982) Reduced ATP concentration as a basis for synaptic transmission failure during hypoxia in the in vitro guinea-pig hippocampus. J. Physiol. 325, 51-65.
102. Lunardi G., Parodi A., Perasso L. et al. (2006) The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience 142, 991-997.
103. Lyons G. E., Mühlebach S., Moser A., Masood R., Paterson B. M., Buckingham M. E. and Perriard J. C. (1991) Developmental regulation of creatine kinase gene expression by myogenic factors in embryonic mouse and chick skeletal muscle. Development 113, 1017-1029.
104. Mak C. S., Waldvogel H. J., Dodd J. R., Gilbert R. T., Lowe M. T., Birch N. P., Faull R. L. and Christie D. L. (2009) Immunohistochemical localisation of the creatine transporter in the rat brain. Neuroscience 163, 571-585.
105. Mancardi M. M., Caruso U., Schiaffino M. C. et al. (2007) Severe epilepsy in X-linked creatine transporter defect (CRTR-D). Epilepsia 48, 1211-1213.
106. Mathews V. P., Barker P. B., Blackband S. J., Chatham J. C. and Bryan R. N. (1995) Cerebral metabolites in patients with acute and subacute strokes: Concentrations determined by quantitative proton MR spectroscopy. AJR Am. J. Roentgenol. 165, 633-638.
107. Matthews R. T., Ferrante R. J., Klivenyi P., Yang L., Klein A. M., Mueller G., Kaddurah-Daouk R. and Beal M. F. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157, 142-149.
108. Mattiazzi M., D'Aurelio M., Gajewski C. D., Martushova K., Kiaei M., Beal M. F. and Manfredi G. (2002) Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277, 29626-29633.
109. McBride H. M., Neuspiel M. and Wasiak S. (2006) Mitochondria: More than just a powerhouse. Curr. Biol. 16, R551-R560.
110. McGuire D. M., Gross M. D., Van Pilsum J. F. and Towle H. C. (1984) Repression of rat kidney L-arginine: Glycine amidinotransferase synthesis by creatine at a pretranslational level. J. Biol. Chem. 259, 12034-12038.
111. Mercimek-Mahmutoglu S., Stoeckler-Ipsiroglu S., Adami A. et al. (2006) GAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 67, 480-484.
112. Miller T. J., Hanson R. D. and Yancey P. H. (2000) Developmental changes in organic osmolytes in prenatal and postnatal rat tissues. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 125, 45-56.
113. Möller A. and Hamprecht B. (1989) Creatine transport in cultured cells of rat and mouse brain. J. Neurochem. 52, 544-550.
114. Nakashima T., Tomi M., Katayama K., Tachikawa M., Watanabe M., Terasaki T. and Hosoya K. (2004) Blood-to-retina transport of creatine via creatine transporter (CRT) at the rat inner blood-retinal barrier. J. Neurochem. 89, 1454-1461.
115. Nakashima T., Tomi M., Tachikawa M., Watanabe M., Terasaki T. and Hosoya K. (2005) Evidence for creatine biosynthesis in Mü ller glia. Glia 52, 47-52.
116. Näntö-Salonen K., Komu M., Lundbom N., Heinänen K., Alanen A., Sipilä I. and Simell O. (1999) Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia. Neurology 53, 303-307.
117. Neu A., Neuhoff H., Trube G., Fehr S., Ullrich K., Roeper J. and Isbrandt D. (2002) Activation of GABA(A) receptors by guanidinoacetate: A novel pathophysiological mechanism. Neurobiol. Dis. 11, 298-307.
118. Nicholls D. and Attwell D. (1990) The release and uptake of excitatory amino acids. Trends Pharmacol. Sci. 11, 462-468.
119. Obrenovitch T. P., Garofalo O., Harris R. J., Bordi L., Ono M., Momma F., Bachelard H. S. and Symon L. (1988) Brain tissue concentrations of ATP, phosphocreatine, lactate, and tissue pH in relation to reduced cerebral blood flow following experimental acute middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 8, 866-874.
120. O'Gorman E., Beutner G., Dolder M., Koretsky A. P., Brdiczka D. and Wallimann T. (1997) The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 414, 253-257.
121. Ohtsuki S. (2004) New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system. Biol. Pharm. Bull. 27, 1489-1496.
122. Ohtsuki S., Tachikawa M., Takanaga H., Shimizu H., Watanabe M., Hosoya K. and Terasaki T. (2002) The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J. Cereb. Blood Flow Metab. 22, 1327-1335.
123. Oliet S. H., Piet R. and Poulain D. A. (2001) Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science 292, 923-926.
124. Parker W. D., Boyson S. J. and Parks J. K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719-723.
125. - -creatine transporter: Functional, molecular characterization and localization. J. Physiol. 545, 133-144.
126. (+)/ Cl(-)/creatine transporter activity and expression in rat brain synaptosomes. Neuroscience 165, 53-60.
127. Perasso L., Cupello A., Lunardi G. L., Principato C., Gandolfo C. and Balestrino M. (2003) Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. Brain Res. 974, 37-42.
128. Perasso L., Lunardi G. L., Risso F. et al. (2008) Protective effects of some creatine derivatives in brain tissue anoxia. Neurochem. Res. 33, 765-775.
129. Peres M., Bourgeois D., Roussel S. et al. (1992) Two-dimensional 1H spectroscopic imaging for evaluating the local metabolic response to focal ischemia in the conscious rat. NMR Biomed. 5, 11-19.
130. Póo-Argü elles P., Arias A., Vilaseca M. A., Ribes A., Artuch R., Sans- Fito A., Moreno A., Jakobs C. and Salomons G. (2006) X-Linked creatine transporter deficiency in two patients with severe mental retardation and autism. J. Inherit. Metab. Dis. 29, 220-223.
131. Primeau A. J., Adhihetty P. J. and Hood D. A. (2002) Apoptosis in heart and skeletal muscle. Can. J. Appl. Physiol. 27, 349-395.
132. Ratnakumari L., Qureshi I. A., Butterworth R. F., Marescau B. and De Deyn P. P. (1996) Arginine-related guanidino compounds and nitric oxide synthase in the brain of ornithine transcarbamylase deficient spf mutant mouse: Effect of metabolic arginine deficiency. Neurosci. Lett. 215, 153-156.
133. Renema W. K., Schmidt A., van Asten J. J., Oerlemans F., Ullrich K., Wieringa B., Isbrandt D. and Heerschap A. (2003) MR spectroscopy of muscle and brain in guanidinoacetate methyltransferase (GAMT)-deficient mice: Validation of an animal model to study creatine deficiency. Magn. Reson. Med. 50, 936-943.
134. Rosenberg E. H., Almeida L. S., Kleefstra T. et al. (2004) High prevalence of SLC6A8 deficiency in X-linked mental retardation. Am. J. Hum. Genet. 75, 97-105.
135. Rosenfeld J., King R. M., Jackson C. E. et al. (2008) Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph. Lateral Scler. 9, 266-272.
136. Ross C. A. (2004) Huntington's disease: New paths to pathogenesis. Cell 118, 4-7.
137. Ryu H. and Ferrante R. J. (2005) Emerging chemotherapeutic strategies for Huntington's disease. Expert Opin. Emerg. Drugs. 10, 345-363.
138. Salomons G. S., van Dooren S. J., Verhoeven N. M., Cecil K. M., Ball W. S., de Grauw T. J. and Jakobs C. (2001) X-linked creatinetransporter gene (SLC6A8) defect: A new creatine-deficiency syndrome. Am. J. Hum. Genet. 68, 1497-1500.
139. Saltarelli M. D., Bauman A. L., Moore K. R., Bradley C. C. and Blakely R. D. (1996) Expression of the rat brain creatine transporter in situ and in transfected HeLa cells. Dev. Neurosci. 18, 524-534.
140. Sandell L. L., Guan X. J., Ingram R. and Tilghman S. M. (2003) Gatm, a creatine synthesis enzyme, is imprinted in mouse placenta. Proc. Natl Acad. Sci. USA 100, 4622-4627.
141. Schlattner U., Tokarska-Schlattner M. and Wallimann T. (2006) Mitochondrial creatine kinase in human health and disease. Biochim. Biophys. Acta 1762, 164-180.
142. Schloss P., Mayser W. and Betz H. (1994) The putative rat choline transporter CHOT1 transports creatine and is highly expressed in neural and muscle-rich tissues. Biochem. Biophys. Res. Commun. 198, 637-645.
143. Schmidt A., Marescau B., Boehm E. A. et al. (2004) Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum. Mol. Genet. 13, 905-921.
144. Schulze A. (2003) Creatine deficiency syndromes. Mol. Cell. Biochem. 244, 143-150.
145. Schulze A. and Battini R. (2007) Pre-symptomatic treatment of creatine biosynthesis defects. Subcell. Biochem. 46, 167-181.
146. Schulze A., Hess T., Wevers R. et al. (1997) Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: Diagnostic tools for a new inborn error of metabolism. J. Pediatr. 131, 626-631.
147. Schulze A., Mayatepek E., Bachert P., Marescau B., De Deyn P. P. and Rating D. (1998) Therapeutic trial of arginine restriction in creatine deficiency syndrome. Eur. J. Pediatr. 157, 606-607.
148. Schulze A., Ebinger F., Rating D. and Mayatepek E. (2001) Improving treatment of guanidinoacetate methyltransferase deficiency: Reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Mol. Genet. Metab. 74, 413-419.
149. Schulze A., Bachert P., Schlemmer H. et al. (2003) Lack of creatine in muscle and brain in an adult with GAMT deficiency. Ann. Neurol. 53, 248-251.
150. Schulze A., Hoffmann G. F., Bachert P., Kirsch S., Salomons G. S., Verhoeven N. M. and Mayatepek E. (2006) Presymptomatic treatment of neonatal guanidinoacetate methyltransferase deficiency. Neurology 67, 719-721.
151. Shefner J. M., Cudkowicz M. E., Schoenfeld D. et al. (2004) A clinical trial of creatine in ALS. Neurology 63, 1656-1661.
152. Sijens P. E., Verbruggen K. T., Oudkerk M., van Spronsen F. J. and Soorani-Lunsing R. J. (2005) 1H-MR spectroscopy of the brain in Cr transporter defect. Mol. Genet. Metab. 86, 421-422.
153. Da Silva R. P., Nissim I., Brosnan M. E. and Brosnan J. T. (2009) Creatine synthesis: Hepatic metabolism of guanidinoacetate and creatine in the rat in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 296, E256-E261.
154. Sipilä I. (1980) Inhibition of arginine-glycine amidinotransferase by ornithine. A possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia. Biochim. Biophys. Acta 613, 79-84.
155. Snow R. J. and Murphy R. M. (2001) Creatine and the creatine transporter: A review. Mol. Cell. Biochem. 224, 169-181.
156. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell 89, 93-103.
157. Stöckler S., Holzbach U., Hanefeld F., Marquardt I., Helms G., Requart M., Hanicke W. and Frahm J. (1994) Creatine deficiency in the brain: A new, treatable inborn error of metabolism. Pediatr. Res. 36, 409-413.
158. Stöckler S., Hanefeld F. and Frahm J. (1996a) Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 348, 789-790. (Pubitemid 26308483)
159. Stöckler S., Isbrandt D., Hanefeld F., Schmidt B. and von Figura K. (1996b) Guanidinoacetate methyltransferase deficiency: The first inborn error of creatine metabolism in man. Am. J. Hum. Genet. 58, 914-922. (Pubitemid 26115162)
160. Stöckler S., Schutz P. W. and Salomons G. S. (2007) Cerebral creatine deficiency syndromes: Clinical aspects, treatment and pathophysiology. Subcell. Biochem. 46, 149-166.
161. Streijger F., Oerlemans F., Ellenbroek B. A., Jost C. R., Wieringa B. and Van der Zee C. E. (2005) Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav. Brain Res. 157, 219-234.
162. Stromberger C., Bodamer O. A. and Stöckler-Ipsiroglu S. (2003) Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J. Inherit. Metab. Dis. 26, 299-308.
163. Swerdlow R. H., Parks J. K., Cassarino D. S. et al. (1998) Mitochondria in sporadic amyotrophic lateral sclerosis. Exp. Neurol. 153, 135-142.
164. Tachikawa M., Fukaya M., Terasaki T., Ohtsuki S. and Watanabe M. (2004) Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur. J. Neurosci. 20, 144-160.
165. Tachikawa M., Fujinawa J., Takahashi M. et al. (2008) Expression and possible role of creatine transporter in the brain and at the bloodcerebrospinal fluid barrier as a transporting protein of guanidinoacetate, an endogenous convulsant. J. Neurochem. 107, 768-778.
166. Tachikawa M., Kasai Y., Yokoyama R., Fujinawa J., Ganapathy V., Terasaki T. and Hosoya K. (2009) The blood-brain barrier transport and cerebral distribution of guanidinoacetate in rats: Involvement of creatine and taurine transporters. J. Neurochem. 111, 499-509.
167. Tarnopolsky M. A. and Beal M. F. (2001) Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 49, 561-574.
168. Thomas B. and Beal M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16(R2), R183-R194.
169. Tiraboschi P., Hansen L. A., Thal L. J. and Corey-Bloom J. (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989.
170. Torremans A., Marescau B., Possemiers I., Van Dam D., D'Hooge R., Isbrandt D. and De Deyn P. P. (2005) Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency. J. Neurol. Sci. 231, 49-55.
171. Valayannopoulos V., Boddaert N., Mention K. et al. (2009) Secondary creatine deficiency in ornithine delta-aminotransferase deficiency. Mol. Genet. Metab. 97, 109-113.
172. Valle D., Walser M., Brusilow S., Kaiser-Kupfer M. I. and Takki K. (1981) Gyrate atrophy of the choroid and retina. Biochemical considerations and experience with an arginine-restricted diet. Ophthalmology 88, 325-330. (Pubitemid 11098634)
173. Valtonen M., Näntö-Salonen K., Jääskeläinen S., Heinänen K., Alanen A., Heinonen O. J., Lundbom N., Erkintalo M. and Simell O. (1999) Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia. J. Inherit. Metab. Dis. 22, 855-866.
174. Van Pilsum J. F., Stephens G. C. and Taylor D. (1972) Distribution of creatine, guanidinoacetate and enzymes for their biosynthesis in the animal kingdom. Implications for phylogeny. Biochem. J. 126, 325-345.
175. Virgintino D., Monaghan P., Robertson D., Errede M., Bertossi M., Ambrosi G. and Roncali L. (1997) An immunohistochemical and morphometric study on astrocytes and microvasculature in the human cerebral cortex. Histochem. J. 29, 655-660.
176. Wallimann T., Wyss M., Brdiczka D., Nicolay K. and Eppenberger H. M. (1992) Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The'phosphocreatine circuit' for cellular energy homeostasis. Biochem. J. 281, 21-40.
177. Wallimann T., Dolder M., Schlattner U., Eder M., Hornemann T., O'Gorman E., Ruck A. and Brdiczka D. (1998) Some new aspects of creatine kinase (CK): Compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors 8, 229-234.
178. Wallimann T., Tokarska-Schlattner M., Neumann D. et al. (2007) The phosphocreatine circuit: Molecular and cellular physiology of creatine kinases, sensitivity to free radicals and enhancement of creatine supplementation, in Molecular Systems Bioenergetics: Energy for Life, Basic Principles, Organization and Dynamics of Cellular Energetics (Saks V. A., ed.), pp. 195-264. Wiley VCHPublisher Co, Weinheim.
179. Wang Y. and Li S. J. (1998) Differentiation of metabolic concentrations between gray matter and white matter of human brain by in vivo 1H magnetic resonance spectroscopy. Magn. Reson. Med. 39, 28-33.
180. Wang T., Milam A. H., Steel G. and Valle D. (1996) A mouse model of gyrate atrophy of the choroid and retina. Early retinal pigment epithelium damage and progressive retinal degeneration. J. Clin. Invest. 97, 2753-2762.
181. Wang L., Zhang Y., Shao M. and Zhang H. (2007) Spatiotemporal expression of the creatine metabolism related genes agat, gamt and ct1 during zebrafish embryogenesis. Int. J. Dev. Biol. 51, 247-253.
182. Wenk G. L. (2003) Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry 64(Suppl 9), 7-10.
183. Whittingham T. S. and Lipton P. (1981) Cerebral synaptic transmission during anoxia is protected by creatine. J. Neurochem. 37, 1618-1621.
184. Wick M., Fujimori H., Michaelis T. and Frahm J. (1999) Brain water diffusion in normal and creatine-supplemented rats during transient global ischemia. Magn. Reson. Med. 42, 798-802.
185. Wilcken B., Fagan E., Sim K., Carpenter K. H. and Salomons G. S. (2008) Creatine transporter defect: Results of 6 months' treatment. J. Inherit. Metab. Dis. 31(Suppl 1), 70.
186. Wong P. C., Pardo C. A., Borchelt D. R., Lee M. K., Copeland N. G., Jenkins N. A., Sisodia S. S., Cleveland D. W. and Price D. L. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105-1116.
187. Wyss M. and Kaddurah-Daouk R. (2000) Creatine and creatinine metabolism. Physiol. Rev. 80, 1107-1213.
188. Zhu S., Li M., Figueroa B. E., Liu A. et al. (2004) Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 24, 5909-5912.
189. +-ATPase and creatine kinase activities in rat striatum. Metab. Brain Dis. 21, 41-50.